Endpoints for clinical trials in type 1 diabetes drug development

Galderisi, AlfonsoMarks, Brynn E.DiMeglio, Linda A.de Beaufort, Carine2024-12-132024-12-132024Galderisi A, Marks BE, DiMeglio LA, de Beaufort C. Endpoints for clinical trials in type 1 diabetes drug development. Lancet Diabetes Endocrinol. 2024;12(5):297-299. doi:10.1016/S2213-8587(24)00097-4https://hdl.handle.net/1805/45017en-USPublisher PolicyType 1 diabetes mellitusDrug developmentHypoglycemic agentsEndpoint determinationEndpoints for clinical trials in type 1 diabetes drug developmentArticle